Prediction Case File
YouTubeEvaluation Complete

In this video, I break down whether Eli Lilly stock is still a strong buy in 2026 after an explosive year of growth. I will walk you through the company’s latest earnings report, revenue guidance, blockbuster obesity drugs like Mounjaro and Zepbound, and its powerful pipeline including orforglipron

1 extracted signal · 1 resolved · 0 still active

Rick Orford - Trading Stocks and Options For All profile imageRick Orford - Trading Stocks and Options For AllIndependent analyst profile
Source published
18 Feb 2026, 01:00 UTC
Recorded by Tahlil Plus
18 May 2026, 20:24 UTC
Video preview for In this video, I break down whether Eli Lilly stock is still a strong buy in 2026 after an explosive year of growth. I will walk you through the company’s latest earnings report, revenue guidance, blockbuster obesity drugs like Mounjaro and Zepbound, and its powerful pipeline including orforglipron
Source overview

AI-generated source summary

Eli Lilly and Company (LLY) is showing strong financial performance with significant revenue growth driven by its key products, Mounjaro and Zepbound. The company's robust pipeline, including promising phase 3 trial results for tirzepatide in obesity and various other drug candidates, along with strategic acquisitions, positions it for continued expansion. Analysts maintain a strong buy rating, indicating confidence in future earnings growth and capital gains, supported by a consistent and well-covered dividend. The stock's low beta suggests it's a defensive compounder, offering a combination of growth and stability.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Rick Orford - Trading Stocks and Options For All

Platform-wide history, separate from this source evaluation.

Reliability
45.5
Tracked signals
591
Historical success
31.3%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail